Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study to Determine if Aquamin Modulates Inflammatory Biomarkers in the Blood of Osteoarthritis and Healthy Subjects

This study has been completed.
Information provided by (Responsible Party):
Andrea Doolan, University College Cork Identifier:
First received: March 22, 2011
Last updated: May 14, 2012
Last verified: May 2012

Osteoarthritis (OA) is the most common kind of arthritis and primarily affects the large, weight bearing joints (including the knees, lower back, hips, neck and the feet) and the joints in the hands. OA results from the breakdown of cartilage in joints, leading to joint pain and damage. It affects about 8 million people in the United Kingdom and nearly 27 million people in the United States, most of whom are over the age of 45.

This study aim to determine if Aquamin (as AquaCal and AquaPT) affects molecules of inflammation in the blood of osteoarthritis and healthy subjects.

Condition Intervention Phase
Dietary Supplement: AquaCal
Dietary Supplement: AquaPT
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider)
Primary Purpose: Supportive Care
Official Title: Randomised, Placebo Controlled Study to Determine if Aquamin (as AquaCal and AquaPT) Modulates Inflammatory Biomarkers in the Blood of Osteoarthritis and Healthy Subjects

Resource links provided by NLM:

Further study details as provided by Andrea Doolan, University College Cork:

Primary Outcome Measures:
  • Cytokines [ Time Frame: Baseline (wk 0) & wk 6 ]
    Plasma cytokine concentrations (including TNFα, IL-β, NFκB, COX2 & IL-6)

Secondary Outcome Measures:
  • WOMAC Questionnaire [ Time Frame: Wk0 & Wk6 ]
    Western Ontario and McMaster Universities Arthritis Index

  • Full Blood Count [ Time Frame: Wk0 & Wk6 ]
    Haemaglobin, white cell count, platelet count, haematocrit, differential white count

  • Chemistry Profile [ Time Frame: Wk0 & Wk6 ]
    Including Sodium, Potassium, Chloride, Urea, Creatinine, Protein, Albumin

Enrollment: 36
Study Start Date: March 2011
Study Completion Date: May 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AquaCal
Osteoarthritis and healthy volunteers
Dietary Supplement: AquaCal

AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.

The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg).

Active Comparator: AquaPT
Dietary Supplement: AquaPT

AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.

The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract.

  Show Detailed Description


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

To be considered eligible for enrollment into the study, subjects must;

  • Be able to give written informed consent.
  • Be female and between 18 and 65 years of age.
  • Be a non-pregnant female.
  • Be in generally good health as determined by the investigator.
  • Osteoarthritis patients must have a clinical diagnosis of moderate to severe osteoarthritis.

Exclusion Criteria:

Subjects will be excluded from the study if they meet any of the below criteria;

  • Are less than 18 and greater than 65 years of age.
  • Are pregnant females.
  • Are currently taking probiotics or vitamin supplements, or have taken them in the past 14 days.
  • Have a significant acute or chronic coexisting illness (cardiovascular, gastrointestinal, endocrinological, immunological, metabolic or any condition which contraindicates, in the investigators judgment, entry to the study).
  • Having a condition or taking a medication that the investigator believes would interfere with the objectives of the study, pose a safety risk or confound the interpretation of the study results; to include non-steroidal anti-inflammatory drugs (NSAIDs), steroids and vitamin.
  • Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.
  • Subjects may not be receiving treatment involving experimental drugs.
  • If the subject has been in a recent experimental trial, these must have been completed not less than 30 days prior to this study.
  • Have a malignant disease or any concomitant end-stage organ disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01321281

Cork University Hospital
Cork, Ireland
Sponsors and Collaborators
Andrea Doolan
Principal Investigator: Timothy Dinan University College Cork
  More Information

Responsible Party: Andrea Doolan, Human Studies Manager, University College Cork Identifier: NCT01321281     History of Changes
Other Study ID Numbers: APC026-Marigot
Study First Received: March 22, 2011
Last Updated: May 14, 2012

Keywords provided by Andrea Doolan, University College Cork:

Additional relevant MeSH terms:
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases processed this record on May 25, 2017